The firm, the clinical arm of Quotient Bioresearch, has increased the number of beds in the facility by 50 per cent to 44. The expanded unit has also gained supplementary accreditation by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).
MD Mark Egerton said the expansion “underlines the strength of our Synthesis-to-Clinic platform” and will assist the continued development of the firm’s offering in early drug development.
The investment, financial details of which were not disclosed, follows shortly after the expansion of Quotient’s manufacturing, formulation and pharmaceutical analysis suite at the Nottingham site.
At the time Egerton said that the expansion was it cater for growing customer demand for the RapidFACT (Rapid Formulation development And Clinical Testing) services the firm offers through its partnership with Bend Research.